These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9677534)

  • 41. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
    Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors.
    Lissoni P; Rovelli F; Tisi E; Brivio F; Ardizzoia A; Barni S; Tancini G; Saudelli M; Cesana E; Viganò MG
    J Biol Regul Homeost Agents; 1995; 9(4):146-9. PubMed ID: 8844339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
    Lissoni P; Ardizzoia A; Tisi E; Rossini F; Barni S; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1993; 7(1):34-6. PubMed ID: 8346714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.
    Lissoni P; Barni S; Archili C; Cattaneo G; Rovelli F; Conti A; Maestroni GJ; Tancini G
    Anticancer Res; 1990; 10(3):753-7. PubMed ID: 2142395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
    Huland E; Heinzer H; Huland H
    Hepatogastroenterology; 1999 May; 46 Suppl 1():1257-62. PubMed ID: 10429971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients.
    Lissoni P; Fumagalli E; Malugani F; Ardizzoia A; Bucovec R; Tancini G; Gardani GS
    J Biol Regul Homeost Agents; 2001; 15(2):163-5. PubMed ID: 11501974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
    Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
    Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
    Zhang GJ; Adachi I
    Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease.
    Ardizzoia A; Lissoni P; Brivio F; Tisi E; Perego MS; Grassi MG; Pittalis S; Crispino S; Barni S; Tancini G
    J Biol Regul Homeost Agents; 1992; 6(3):103-7. PubMed ID: 1492596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    Rosenberg SA; White DE
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytokine regulation of iron metabolism: effect of low-dose interleukin-2 subcutaneous therapy on ferritin, transferrin and iron blood concentrations in cancer patients.
    Lissoni P; Cazzaniga M; Ardizzoia A; Rossini F; Fiorelli G; Tancini G; Pittalis S; Barni S
    J Biol Regul Homeost Agents; 1993; 7(1):31-3. PubMed ID: 8346713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2.
    Lissoni P; Bastone A; Barni S; Tancini G; Galli MA
    J Biol Regul Homeost Agents; 1994; 8(2):65-6. PubMed ID: 7863816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?
    Dillman RO; Barth NM; VanderMolen LA; Fong WH; Mahdavi KK; McClure SE
    Cancer Biother Radiopharm; 2011 Jun; 26(3):273-7. PubMed ID: 21711094
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancer.
    Lissoni P; Rovelli F; Tancini G; Tisi E; Rivolta MR; Ardizzoia A; Brivio F
    J Biol Regul Homeost Agents; 1992; 6(4):113-5. PubMed ID: 1338354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.
    Lissoni P; Fumagalli L; Rovelli F; Brivio F; Di Felice G; Majorca F
    Br J Cancer; 1998 Jun; 77(11):1957-60. PubMed ID: 9667674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Melatonin as a new possible anti-inflammatory agent.
    Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
    J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
    Lissoni P; Tisi E; Brivio F; Ardizzoia A; Crispino S; Barni S; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.